Download PDF
Thromb Haemost 2007; 97(04): 503-504
DOI: 10.1160/TH07-03-0176
Editorial Focus
Schattauer GmbH

Hormonal therapy with patch or pill: How much does it matter?

Katrin Schaudig
1   Praxis für Gynaekologische Endokrinologie, Gynaekologicum Hamburg, Germany
,
Christoph Thomssen
2   Klinik und Poliklinik für Gynäkologie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany
› Author Affiliations
Further Information

Publication History

Received 06 March 2007

Accepted 06 March 2007

Publication Date:
24 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Jick H, Derby LE, Myers MW. et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348: 981-983.
    CrossrefPubMedGoogle Scholar
  • 2 Grodstein F, Stampfer M J, Goldhaber S Z. et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348: 983-987.
    CrossrefPubMedGoogle Scholar
  • 3 Daly E, Vessey MP, Hawkins MM. et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348: 977-980.
    CrossrefPubMedGoogle Scholar
  • 4 Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. J Am Med Assoc 2002; 288: 321-333.
    CrossrefPubMedGoogle Scholar
  • 5 The WHI steering committee. Effects of conjugated equine estrogens in postmenopausal women with hysterectomy. J Am Med Assoc 2004; 291: 1701-1712.
    CrossrefPubMedGoogle Scholar
  • 6 Herkert O, Kuhl H, Sandow J. et al. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 2001; 104: 2826-2831.
    CrossrefPubMedGoogle Scholar
  • 7 Scarabin P-Y, Oger E, Plu-Bureau G. for the ESTHER study group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432.
    CrossrefPubMedGoogle Scholar
  • 8 Canonico M, Straczek C, Oger E. et al. Postmenopausal hormone therapy and cardiovascular disease: an overview of main findings. Maturitas 2006; 54: 372-379.
    CrossrefPubMedGoogle Scholar
  • 9 Straczek C, Oger E, Yon de Jonage-Canonico MB. et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112: 3495-3500.
    CrossrefPubMedGoogle Scholar
  • 10 Wu O. Postmenopausal hormone replacement therapy and venous thromboembolism. Gend Med 2005; 2: S18-27. Suppl A
    CrossrefPubMedGoogle Scholar
  • 11 Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in post menopausal women taking low dose hormone therapy: Less effect with transdermal administration?. Thromb Haemost 2007; 97: 558-565.
    Article in Thieme ConnectPubMedGoogle Scholar